Free Trial

Femasys (FEMY) Competitors

Femasys logo
$1.06 +0.05 (+4.95%)
Closing price 04:00 PM Eastern
Extended Trading
$1.05 -0.01 (-0.94%)
As of 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FEMY vs. LUCD, INFU, ICAD, OBIO, MGRM, MBOT, GUTS, EDAP, NSPR, and FONR

Should you be buying Femasys stock or one of its competitors? The main competitors of Femasys include Lucid Diagnostics (LUCD), InfuSystem (INFU), iCAD (ICAD), Orchestra BioMed (OBIO), Monogram Orthopaedics (MGRM), Microbot Medical (MBOT), Fractyl Health (GUTS), Edap Tms (EDAP), InspireMD (NSPR), and FONAR (FONR). These companies are all part of the "medical equipment" industry.

Femasys vs.

Lucid Diagnostics (NASDAQ:LUCD) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 6.8% of Lucid Diagnostics shares are owned by company insiders. Comparatively, 12.3% of Femasys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Femasys has lower revenue, but higher earnings than Lucid Diagnostics. Femasys is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lucid Diagnostics$4.17M34.09-$52.67M-$1.34-0.98
Femasys$1.70M16.19-$14.25M-$0.91-1.11

Lucid Diagnostics presently has a consensus price target of $3.50, suggesting a potential upside of 166.16%. Femasys has a consensus price target of $8.67, suggesting a potential upside of 758.09%. Given Femasys' higher possible upside, analysts clearly believe Femasys is more favorable than Lucid Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lucid Diagnostics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20
Femasys
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Lucid Diagnostics has a net margin of -1,069.87% compared to Femasys' net margin of -1,435.77%. Lucid Diagnostics' return on equity of 0.00% beat Femasys' return on equity.

Company Net Margins Return on Equity Return on Assets
Lucid Diagnostics-1,069.87% N/A -123.54%
Femasys -1,435.77%-141.49%-82.30%

Lucid Diagnostics has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Comparatively, Femasys has a beta of -2.52, indicating that its stock price is 352% less volatile than the S&P 500.

Lucid Diagnostics received 4 more outperform votes than Femasys when rated by MarketBeat users. However, 74.51% of users gave Femasys an outperform vote while only 68.85% of users gave Lucid Diagnostics an outperform vote.

CompanyUnderperformOutperform
Lucid DiagnosticsOutperform Votes
42
68.85%
Underperform Votes
19
31.15%
FemasysOutperform Votes
38
74.51%
Underperform Votes
13
25.49%

In the previous week, Lucid Diagnostics had 6 more articles in the media than Femasys. MarketBeat recorded 6 mentions for Lucid Diagnostics and 0 mentions for Femasys. Lucid Diagnostics' average media sentiment score of -0.24 beat Femasys' score of -0.35 indicating that Lucid Diagnostics is being referred to more favorably in the media.

Company Overall Sentiment
Lucid Diagnostics Neutral
Femasys Neutral

Summary

Lucid Diagnostics beats Femasys on 13 of the 19 factors compared between the two stocks.

Get Femasys News Delivered to You Automatically

Sign up to receive the latest news and ratings for FEMY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FEMY vs. The Competition

MetricFemasysSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$27.51M$4.41B$5.31B$8.42B
Dividend YieldN/A43.63%5.21%4.10%
P/E Ratio-1.2529.2326.7819.69
Price / Sales16.1965.60386.97118.34
Price / CashN/A51.0838.2534.62
Price / Book1.196.206.744.50
Net Income-$14.25M$67.60M$3.23B$248.32M
7 Day Performance-5.61%-0.72%1.49%-0.03%
1 Month Performance-17.21%18.00%11.47%12.72%
1 Year Performance-22.31%21.13%16.57%7.38%

Femasys Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FEMY
Femasys
2.291 of 5 stars
$1.06
+5.0%
$8.67
+717.6%
-21.1%$28.87M$1.70M-1.3130
LUCD
Lucid Diagnostics
3.2022 of 5 stars
$1.10
-2.7%
$3.50
+218.2%
+46.2%$115.92M$4.35M-0.9670Analyst Downgrade
Gap Up
INFU
InfuSystem
2.4543 of 5 stars
$5.48
+2.0%
$13.00
+137.2%
N/A$115.17M$134.86M91.35410Positive News
High Trading Volume
ICAD
iCAD
0.297 of 5 stars
$3.71
+3.1%
N/A+134.4%$101.83M$19.61M-28.54140Analyst Forecast
Gap Up
High Trading Volume
OBIO
Orchestra BioMed
2.8247 of 5 stars
$2.65
flat
$14.20
+435.8%
-46.6%$101.53M$2.64M-1.654Gap Up
MGRM
Monogram Orthopaedics
3.0946 of 5 stars
$2.63
-1.5%
$5.40
+105.3%
+40.7%$92.81M$364,999.00-5.6028Gap Up
MBOT
Microbot Medical
1.8242 of 5 stars
$2.55
+1.2%
$9.00
+252.9%
+156.6%$88.60MN/A-3.1920News Coverage
Positive News
Earnings Report
Gap Up
GUTS
Fractyl Health
1.704 of 5 stars
$1.71
+5.6%
$11.00
+543.3%
-74.7%$83.75M$93,000.00-0.14102Gap Up
EDAP
Edap Tms
1.821 of 5 stars
$2.15
-3.2%
$8.50
+295.3%
-71.0%$79.77M$64.12M-3.31230Earnings Report
Analyst Revision
NSPR
InspireMD
2.2389 of 5 stars
$2.58
-0.8%
$4.50
+74.4%
-4.7%$79.04M$7.01M-3.4450
FONR
FONAR
1.787 of 5 stars
$12.37
-0.2%
N/A-4.9%$76.83M$101.57M10.76480News Coverage
Earnings Report
Analyst Upgrade

Related Companies and Tools


This page (NASDAQ:FEMY) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners